Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875194 | 1.00 | TSHR (0.56) | TSHRHTTKMT2AMAPTMEN1 | |
| SCHEMBL1870579 | 0.84 | HTT (0.51) | TSHRHTTKMT2AMEN1USP2 | |
| SCHEMBL29823338 | 0.84 | HTT (0.51) | TSHRHTTKMT2AMEN1USP2 | |
| SCHEMBL1880362 | 0.80 | KMT2A (0.45) | TSHRKMT2AMAPTMEN1USP2 | |
| SCHEMBL29823527 | 0.76 | MGAM (0.42) | TSHRALDH1A1 | |
| SCHEMBL1874610 | 0.76 | MGAM (0.42) | TSHRALDH1A1 | |
| SCHEMBL1874843 | 0.75 | CXCR4 (0.39) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1879149 | 0.73 | CXCR4 (0.41) | HTTKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL1886813 | 0.70 | HRH3 (0.45) | TSHRKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL28448207 | 0.69 | HTT (0.46) | TSHRHTTKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-115997009-A | Methods and compositions for in vivo transduction of hematopoietic stem and progenitor cells | 美真达治疗公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143302-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022197776-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4051298-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |